EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
[Brackets] indicate matter deleted from existing law.
*sb0144*
SENATE BILL 144
J1 2lr0533
(PRE–FILED)
By: Senator Feldman
Requested: September 22, 2021
Introduced and read first time: January 12, 2022
Assigned to: Finance
A BILL ENTITLED
AN ACT concerning 1
Health – Authorization to Prescribe and Administer Amygdalin – Repeal 2
FOR the purpose of repealing certain provisions of law relating to the prescription, 3
administration, and regulation of amygdalin; and generally relating to amygdalin. 4
BY repealing 5
Article – Health – General 6
Section 18–302 7
Annotated Code of Maryland 8
(2019 Replacement Volume and 2021 Supplement) 9
SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 10
That the Laws of Maryland read as follows: 11
Article – Health – General 12
[18–302. 13
(a) Except as provided in subsection (b) of this section, a physician may prescribe 14
or administer amygdalin to treat cancer. 15
(b) (1) A hospital or health facility may not restrict or prohibit the use of 16
amygdalin that a physician, with the consent of a patient, prescribes for or administers to 17
the patient. 18
(2) (i) The Department may restrict or prohibit the use of amygdalin in 19
the treatment of a patient if, after a hearing, the Department finds that the manner in 20
which the amygdalin is prescribed or administered is harmful to the patient. 21
2 SENATE BILL 144
(ii) The Department shall adopt rules and regulations for hearings 1
under this paragraph. 2
(c) The Department and the State Board of Pharmacy shall regulate the 3
manufacture, distribution, and sale of amygdalin for use in this State, but only to ensure 4
that the amygdalin is not adulterated, contaminated by microorganisms, or misbranded.] 5
SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 6
October 1, 2022. 7